Early impact of treatment with tiotropium, long-acting anticholinergic preparation, in patients with COPD – real-life experience from an observational study
Karina Jahnz-Różyk,1 Pawel Szepiel2 1Department of Immunology and Clinical Allergology, Military Institute of Medicine, Warsaw, Poland; 2Boehringer Ingelheim Sp. z o.o., Warsaw, Poland Background: Long-acting inhaled bronchodilators, including anticholinergic tiotropium, are recommended...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Dove Medical Press
2015-03-01
|
| Series: | International Journal of COPD |
| Online Access: | http://www.dovepress.com/early-impact-of-treatment-with-tiotropium-long-acting-anticholinergic--peer-reviewed-article-COPD |
| _version_ | 1819137363129925632 |
|---|---|
| author | Jahnz-Różyk K Szepiel P |
| author_facet | Jahnz-Różyk K Szepiel P |
| author_sort | Jahnz-Różyk K |
| collection | DOAJ |
| description | Karina Jahnz-Różyk,1 Pawel Szepiel2 1Department of Immunology and Clinical Allergology, Military Institute of Medicine, Warsaw, Poland; 2Boehringer Ingelheim Sp. z o.o., Warsaw, Poland Background: Long-acting inhaled bronchodilators, including anticholinergic tiotropium, are recommended for the maintenance therapy of chronic obstructive pulmonary disease (COPD). It has been shown in a number of studies that treatment with tiotropium alleviates symptoms, improves exercise tolerance, health status, and reduces exacerbations in patients with moderate to very severe stage COPD.Aim: The aim of this noninterventional study was to observe the early effects of the maintenance treatment with tiotropium in patients with COPD of different severities, who had been previously treated on a regular basis, or as required, with at least one short-acting bronchodilator, in a real-life setting in Poland. The effect of the treatment was assessed through the collection of COPD Assessment Test (CAT) data.Patients and methods: The MATHS clinical study was an observational, noninterventional, open-label, prospective, uncontrolled, single-arm, postmarketing, surveillance, real-life study conducted with the involvement of 236 pulmonology clinics based in Poland. The tiotropium observational period was 3 months. The health and COPD status was measured with the CAT questionnaire. The primary efficacy endpoint was the mean change from the baseline in the total CAT score at the end of the 3-month observational period.Results: Patients treated with 18 µg of tiotropium once daily for 3 months showed a statistically significant result, with a clinically meaningful mean reduction (improvement) of 7.0 points in the total CAT score. The improvement was slightly greater in patients with more severe COPD; the mean change in the total CAT score was 7.6 in the subgroup of patients with more severe COPD and 6.7 points in the subgroup of patients with moderate COPD. Conclusion: Results of this real-life study provide further support for the use of tiotropium as a first-line maintenance treatment for patients with COPD of different severities in Poland. Keywords: Spiriva® HandiHaler®, chronic obstructive pulmonary disease, GOLD classification, CAT |
| first_indexed | 2024-12-22T10:49:41Z |
| format | Article |
| id | doaj.art-e3d14de534cb49ff805485cf1a1fb361 |
| institution | Directory Open Access Journal |
| issn | 1178-2005 |
| language | English |
| last_indexed | 2024-12-22T10:49:41Z |
| publishDate | 2015-03-01 |
| publisher | Dove Medical Press |
| record_format | Article |
| series | International Journal of COPD |
| spelling | doaj.art-e3d14de534cb49ff805485cf1a1fb3612022-12-21T18:28:50ZengDove Medical PressInternational Journal of COPD1178-20052015-03-012015Issue 161362320901Early impact of treatment with tiotropium, long-acting anticholinergic preparation, in patients with COPD – real-life experience from an observational studyJahnz-Różyk KSzepiel PKarina Jahnz-Różyk,1 Pawel Szepiel2 1Department of Immunology and Clinical Allergology, Military Institute of Medicine, Warsaw, Poland; 2Boehringer Ingelheim Sp. z o.o., Warsaw, Poland Background: Long-acting inhaled bronchodilators, including anticholinergic tiotropium, are recommended for the maintenance therapy of chronic obstructive pulmonary disease (COPD). It has been shown in a number of studies that treatment with tiotropium alleviates symptoms, improves exercise tolerance, health status, and reduces exacerbations in patients with moderate to very severe stage COPD.Aim: The aim of this noninterventional study was to observe the early effects of the maintenance treatment with tiotropium in patients with COPD of different severities, who had been previously treated on a regular basis, or as required, with at least one short-acting bronchodilator, in a real-life setting in Poland. The effect of the treatment was assessed through the collection of COPD Assessment Test (CAT) data.Patients and methods: The MATHS clinical study was an observational, noninterventional, open-label, prospective, uncontrolled, single-arm, postmarketing, surveillance, real-life study conducted with the involvement of 236 pulmonology clinics based in Poland. The tiotropium observational period was 3 months. The health and COPD status was measured with the CAT questionnaire. The primary efficacy endpoint was the mean change from the baseline in the total CAT score at the end of the 3-month observational period.Results: Patients treated with 18 µg of tiotropium once daily for 3 months showed a statistically significant result, with a clinically meaningful mean reduction (improvement) of 7.0 points in the total CAT score. The improvement was slightly greater in patients with more severe COPD; the mean change in the total CAT score was 7.6 in the subgroup of patients with more severe COPD and 6.7 points in the subgroup of patients with moderate COPD. Conclusion: Results of this real-life study provide further support for the use of tiotropium as a first-line maintenance treatment for patients with COPD of different severities in Poland. Keywords: Spiriva® HandiHaler®, chronic obstructive pulmonary disease, GOLD classification, CAThttp://www.dovepress.com/early-impact-of-treatment-with-tiotropium-long-acting-anticholinergic--peer-reviewed-article-COPD |
| spellingShingle | Jahnz-Różyk K Szepiel P Early impact of treatment with tiotropium, long-acting anticholinergic preparation, in patients with COPD – real-life experience from an observational study International Journal of COPD |
| title | Early impact of treatment with tiotropium, long-acting anticholinergic preparation, in patients with COPD – real-life experience from an observational study |
| title_full | Early impact of treatment with tiotropium, long-acting anticholinergic preparation, in patients with COPD – real-life experience from an observational study |
| title_fullStr | Early impact of treatment with tiotropium, long-acting anticholinergic preparation, in patients with COPD – real-life experience from an observational study |
| title_full_unstemmed | Early impact of treatment with tiotropium, long-acting anticholinergic preparation, in patients with COPD – real-life experience from an observational study |
| title_short | Early impact of treatment with tiotropium, long-acting anticholinergic preparation, in patients with COPD – real-life experience from an observational study |
| title_sort | early impact of treatment with tiotropium long acting anticholinergic preparation in nbsp patients with copd ndash real life experience from nbsp an nbsp observational study |
| url | http://www.dovepress.com/early-impact-of-treatment-with-tiotropium-long-acting-anticholinergic--peer-reviewed-article-COPD |
| work_keys_str_mv | AT jahnzroacutezykk earlyimpactoftreatmentwithtiotropiumlongactinganticholinergicpreparationinnbsppatientswithcopdndashreallifeexperiencefromnbspannbspobservationalstudy AT szepielp earlyimpactoftreatmentwithtiotropiumlongactinganticholinergicpreparationinnbsppatientswithcopdndashreallifeexperiencefromnbspannbspobservationalstudy |